McEwan, Phil, Morgan, Angharad R, Boyce, Rebecca, Bergenheim, Klas, Gause-Nilsson, Ingrid AM, Bhatt, Deepak L, Leiter, Lawrence A, Johansson, Peter A, Mosenzon, Ofri, Cahn, Avivit et al (show 1 more authors)
(2021)
The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial.
DIABETES OBESITY & METABOLISM, 23 (4).
pp. 1020-1029.
Abstract
<h4>Aim</h4>To undertake a cost-effectiveness analysis of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus (T2DM), using both directly observed events in the DECLARE-TIMI 58 trial and surrogate risk factors to predict endpoints not captured within the trial.<h4>Methods</h4>An established T2DM model was adapted to integrate survival curves derived from the DECLARE-TIMI 58 trial, and extrapolated over a lifetime for all-cause mortality, hospitalization for heart failure, stroke, myocardial infarction, hospitalization for unstable angina, and end-stage kidney disease. The economic analysis considered the overall DECLARE trial population, as well as reported patient subgroups. Total and incremental costs, life-years and quality-adjusted life-years associated with dapagliflozin versus placebo were estimated from the perspective of the UK healthcare payer.<h4>Results</h4>In the UK setting, treatment with dapagliflozin compared to placebo was estimated to be dominant, with an expected increase in quality-adjusted life-years from 10.43 to 10.48 (+0.06) and a reduction in lifetime total costs from £39 451 to £36 899 (-£2552). Across all patient subgroups, dapagliflozin was estimated to be dominant, with the greatest absolute benefit in the prior heart failure subgroup (incremental lifetime costs -£4150 and quality-adjusted life-years +0.11).<h4>Conclusions</h4>The results of this study demonstrate that dapagliflozin compared to placebo appears to be cost-effective, when considering evidence reported from the DECLARE-TIMI 58 trial, at established UK willingness-to-pay thresholds. The findings highlight the potential of dapagliflozin to have a meaningful impact in reducing the economic burden of T2DM and its associated complications across a broad T2DM population.
Item Type: | Article |
---|---|
Uncontrolled Keywords: | cost-effectiveness, dapagliflozin, SGLT2 inhibitor, type 2 diabetes |
Depositing User: | Symplectic Admin |
Date Deposited: | 11 Feb 2021 10:37 |
Last Modified: | 18 Jan 2023 23:00 |
DOI: | 10.1111/dom.14308 |
Open Access URL: | https://doi.org/10.1111/dom.14308 |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3115487 |